Also known as: vaping cannabis · dry herb vaporization · cannabis vaping lung health

Cannabis Vaporization and Respiratory Effects

What the evidence actually says about inhaling vaporized cannabis versus smoking it, and what it does to your lungs.

Sourced and fact-checked
10 cited sources
Published 3 hours ago
How this page was made
↯ The honest take

Vaporizing dry cannabis flower almost certainly exposes your lungs to fewer combustion toxicants than smoking a joint. That's the strongest claim we can make. Whether it's actually 'safe,' improves chronic symptoms long-term, or beats nicotine cessation tools — that's all weaker evidence or unknown. And cannabis oil vape cartridges are a different product entirely, with their own risks including the 2019 EVALI outbreak. Don't confuse the two. If you have asthma, COPD, or a chronic cough, talk to a pulmonologist, not a budtender.

Not Medical Advice

This article is not medical advice. It summarizes published research on cannabis vaporization and lung health. It does not replace consultation with a physician, pulmonologist, or licensed medical cannabis clinician. If you have asthma, COPD, a history of pneumothorax, pulmonary fibrosis, or any chronic respiratory condition, talk to a doctor before inhaling anything — including cannabis vapor.

Plain-Language Summary

When you smoke cannabis, combustion produces tar, carbon monoxide, polycyclic aromatic hydrocarbons (PAHs), benzene, and other toxicants — many of the same compounds in tobacco smoke, minus nicotine [1][2]. Dry herb vaporizers heat cannabis to roughly 180–210°C, hot enough to volatilize cannabinoids and terpenes but below the temperature at which most combustion byproducts form. Laboratory analysis confirms vaporized cannabis aerosol contains substantially less tar, CO, and PAHs than smoke from the same plant material [1][3].

That's the cleanest finding in this field. Almost everything else — long-term lung function, cancer risk, asthma effects, COPD outcomes — is either weakly studied or not studied at all in vaporizer users specifically.

A critical distinction: 'vaping cannabis' can mean (a) a desktop or portable dry-herb vaporizer using flower, or (b) a battery-powered cartridge containing cannabis oil, often with cutting agents. These have very different risk profiles. The 2019 EVALI outbreak (e-cigarette or vaping-associated lung injury) was overwhelmingly tied to illicit THC oil cartridges containing vitamin E acetate, not to dry-herb vaporization [4].

What Probably Works

Reducing exposure to combustion toxicants by switching from smoking to dry-herb vaporization. Strong evidence Multiple analytical chemistry studies have shown vaporizer aerosol contains dramatically lower levels of ammonia, hydrogen cyanide, CO, PAHs, and tar than cannabis smoke at equivalent cannabinoid delivery [1][3].

Reducing self-reported respiratory symptoms in regular cannabis users who switch to vaporizers. Weak / limited A randomized crossover trial by Abrams et al. (2007) showed vaporization delivered comparable plasma THC to smoking with less CO exposure [1]. A subsequent observational study by Earleywine and Barnwell (2007) found that regular cannabis users who used vaporizers reported fewer respiratory symptoms (cough, phlegm, tight chest) than those who smoked, with the effect strongest in heavier users [5]. This is suggestive but not definitive — it's cross-sectional and self-reported.

Delivering measurable, predictable doses of cannabinoids. Strong evidence Vaporization produces plasma THC curves similar to smoking, making it a reasonable inhaled delivery method for clinical research [1][6].

What Might Work

Improving chronic bronchitis symptoms in habitual cannabis smokers who switch. Weak / limited One pilot study in heavy cannabis smokers with respiratory symptoms found that one month of vaporizer use was associated with improvement in self-reported symptoms and some pulmonary function measures [7]. The sample was small, uncontrolled, and short. Promising signal, not proof.

Harm reduction for medical patients who require inhaled cannabis. Weak / limited For patients who genuinely benefit from rapid-onset inhaled cannabinoids — for example, breakthrough pain or nausea where oral edibles are too slow — vaporization is the most studied lower-toxicant alternative. Several medical cannabis programs and harm-reduction guidelines recommend vaporizers over joints for this reason [2][8], though the evidence base is mechanistic and short-term, not long-term outcome data.

What Doesn't Work or Has Weak Evidence

'Vaping is completely safe.' No data No inhaled aerosol is risk-free. Even pure cannabinoid and terpene vapor irritates airways in some users, and the long-term effects of repeatedly heating terpenes to 200°C+ are not well characterized.

'Vaporizers prevent lung cancer.' No data We don't have epidemiological data on cancer outcomes in cannabis vaporizer users. The toxicant-reduction data make this plausible compared to smoking, but plausibility is not evidence.

'Vaporizing at lower temperatures gives you only the medicinal compounds.' Anecdote The 'temperature dial = pick your effect' folklore in vaping forums is loosely based on cannabinoid and terpene boiling points but oversimplifies a complex chemistry. There's no clinical trial showing 180°C gives different therapeutic outcomes than 200°C.

Cannabis oil vape cartridges as a 'cleaner' alternative. Disputed Some regulated-market distillate carts test clean for major contaminants. But the category as a whole — including unregulated and grey-market products — was responsible for thousands of EVALI hospitalizations and dozens of deaths in 2019, primarily due to vitamin E acetate cutting agents [4]. Cartridges are not interchangeable with dry-herb vaporizers in risk profile.

What We Don't Know

Comparison With Standard Treatments

For most respiratory conditions, inhaled cannabis is not a standard treatment and is not a substitute for one. Asthma is managed with inhaled corticosteroids and bronchodilators; COPD with bronchodilators, pulmonary rehab, and smoking cessation; chronic cough with workup and targeted treatment. None of these are replaced by cannabis vaporization.

Where vaporization enters the conversation:

Risks

Acute airway irritation. Coughing, throat irritation, and bronchospasm can occur, especially with high-temperature or high-potency vapor.

Bronchitis-like symptoms. Habitual smokers transitioning to vaporizers often improve, but vaporizer-only users can still report cough and phlegm, particularly at higher use frequencies [5][7].

EVALI (oil cartridges). Vitamin E acetate and other cutting agents in illicit THC vape cartridges caused acute lipoid-like pneumonitis in 2019, with confirmed hospitalizations exceeding 2,800 and 68 deaths in the U.S. [4]. Regulated dry-herb vaporization was not implicated.

Pneumothorax and bullous lung disease have been reported in heavy cannabis smokers in case series [10]; whether vaporization carries the same risk is unknown.

Impaired driving and cognition from THC are unchanged by route of administration — vaporized THC impairs you just like smoked THC. See cannabis and driving.

Contamination. Cannabis flower can carry pesticide residues, mold (including Aspergillus), and heavy metals, all of which can be aerosolized by a vaporizer. Lab-tested product from regulated markets reduces but does not eliminate this risk.

Dependence and cannabis use disorder are route-agnostic risks of regular use; see cannabis use disorder.

Sources

  1. Peer-reviewed Abrams DI, Vizoso HP, Shade SB, Jay C, Kelly ME, Benowitz NL. Vaporization as a smokeless cannabis delivery system: a pilot study. Clinical Pharmacology & Therapeutics. 2007;82(5):572-578.
  2. Book National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press; 2017.
  3. Peer-reviewed Gieringer D, St. Laurent J, Goodrich S. Cannabis vaporizer combines efficient delivery of THC with effective suppression of pyrolytic compounds. Journal of Cannabis Therapeutics. 2004;4(1):7-27.
  4. Government Centers for Disease Control and Prevention. Outbreak of Lung Injury Associated with the Use of E-Cigarette, or Vaping, Products. Final update February 25, 2020.
  5. Peer-reviewed Earleywine M, Barnwell SS. Decreased respiratory symptoms in cannabis users who vaporize. Harm Reduction Journal. 2007;4:11.
  6. Peer-reviewed Hazekamp A, Ruhaak R, Zuurman L, van Gerven J, Verpoorte R. Evaluation of a vaporizing device (Volcano) for the pulmonary administration of tetrahydrocannabinol. Journal of Pharmaceutical Sciences. 2006;95(6):1308-1317.
  7. Peer-reviewed Van Dam NT, Earleywine M. Pulmonary function in cannabis users: Support for a clinical trial of the vaporizer. International Journal of Drug Policy. 2010;21(6):511-513.
  8. Peer-reviewed MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. European Journal of Internal Medicine. 2018;49:12-19.
  9. Peer-reviewed Meehan-Atrash J, Luo W, Strongin RM. Toxicant Formation in Dabbing: The Terpene Story. ACS Omega. 2017;2(9):6112-6117.
  10. Peer-reviewed Tashkin DP. Effects of marijuana smoking on the lung. Annals of the American Thoracic Society. 2013;10(3):239-247.

How this page was made

Generation history

May 14, 2026
Fact-check pass — raised 3 flags
May 14, 2026
Initial draft

Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.